Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients.

[1]  V. Rickerts,et al.  Breakthrough zygomycosis on posaconazole prophylaxis after allogeneic stem cell transplantation , 2009, Transplant infectious disease : an official journal of the Transplantation Society.

[2]  U. Fuhr,et al.  Factors Influencing Pharmacokinetics of Prophylactic Posaconazole in Patients Undergoing Allogeneic Stem Cell Transplantation , 2009, Antimicrobial Agents and Chemotherapy.

[3]  T. Barbui,et al.  Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO). , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  P. Mann,et al.  Impact of Antifungal Prophylaxis on Colonization and Azole Susceptibility of Candida Species , 2009, Antimicrobial Agents and Chemotherapy.

[5]  D. Lebeaux,et al.  Therapeutic Drug Monitoring of Posaconazole: a Monocentric Study with 54 Adults , 2009, Antimicrobial Agents and Chemotherapy.

[6]  Hermann Einsele,et al.  Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective , 2009, Biology of Blood and Marrow Transplantation.

[7]  Jay B. Varkey,et al.  Pharmacokinetics of Posaconazole Administered Orally or by Nasogastric Tube in Healthy Volunteers , 2009, Antimicrobial Agents and Chemotherapy.

[8]  M. Rinaldi,et al.  Posaconazole Therapeutic Drug Monitoring: a Reference Laboratory Experience , 2009, Antimicrobial Agents and Chemotherapy.

[9]  E. Anaissie,et al.  Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  H. Einsele,et al.  Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology , 2009, Haematologica.

[11]  G. Krishna,et al.  Pharmacokinetics and Absorption of Posaconazole Oral Suspension under Various Gastric Conditions in Healthy Volunteers , 2008, Antimicrobial Agents and Chemotherapy.

[12]  K. Marr,et al.  Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  O. Cornely,et al.  Pharmacokinetics of Oral Posaconazole in Neutropenic Patients Receiving Chemotherapy for Acute Myelogenous Leukemia or Myelodysplastic Syndrome , 2008, Pharmacotherapy.

[14]  G. Socié,et al.  Breakthrough Rhizopus infection on posaconazole prophylaxis following allogeneic stem cell transplantation , 2008, Bone Marrow Transplantation.

[15]  Patricia Muñoz,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  R. Vij,et al.  Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. , 2008, Blood.

[17]  A. Ullmann,et al.  Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: point. , 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

[18]  E. Anaissie,et al.  Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: counterpoint. , 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

[19]  B. Thiers.  Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia , 2008 .

[20]  P. Chandrasekar,et al.  Pharmacokinetics of Oral Posaconazole in Allogeneic Hematopoietic Stem Cell Transplant Recipients with Graft‐versus‐Host Disease , 2007, Pharmacotherapy.

[21]  J. Dipersio,et al.  Results of a Randomized, Double-Blind Trial of Fluconazole (FLU) vs. Voriconazole (VORI) for the Prevention of Invasive Fungal Infections (IFI) in 600 Allogeneic Blood and Marrow Transplant (BMT) Patients. , 2007 .

[22]  L. Pagano,et al.  Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  J. Mehta,et al.  Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy , 2007, Bone Marrow Transplantation.

[24]  J. Lipton,et al.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. , 2007, The New England journal of medicine.

[25]  Jim X. Shen,et al.  A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma. , 2007, Journal of pharmaceutical and biomedical analysis.

[26]  J. Perfect,et al.  Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  D. Winston.  Itraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients , 2006 .

[28]  E. Anaissie,et al.  Pharmacokinetics and Safety of Oral Posaconazole in Neutropenic Stem Cell Transplant Recipients , 2006, Antimicrobial Agents and Chemotherapy.

[29]  D. Loebenberg,et al.  In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and Yeasts , 2006, Antimicrobial Agents and Chemotherapy.

[30]  G. Verhoef,et al.  Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  Russell E. Lewis,et al.  Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. , 2005, The Journal of infectious diseases.

[32]  J. Lipton,et al.  Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  R. Paquette,et al.  Elimination of Aspergillus infection in allogeneic stem cell transplant recipients with long-term itraconazole prophylaxis: prevention is better than treatment. , 2004, Blood.

[34]  L. Bartelt,et al.  Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  W. Leisenring,et al.  Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. , 2004, Blood.

[36]  W. Leisenring,et al.  Cyclophosphamide metabolism is affected by azole antifungals. , 2004, Blood.

[37]  M. Territo,et al.  Intravenous and Oral Itraconazole versus Intravenous and Oral Fluconazole for Long-Term Antifungal Prophylaxis in Allogeneic Hematopoietic Stem-Cell Transplant Recipients: A Multicenter, Randomized Trial , 2003, Annals of Internal Medicine.

[38]  C. Dykewicz.  Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  J. Wingard.  Fungal infections after bone marrow transplant. , 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[40]  M. Levenstein,et al.  Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. , 1995, The Journal of infectious diseases.

[41]  J. L. Goodman,et al.  A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. , 1992, The New England journal of medicine.